Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

(NIS-LL), a quantification of the neurologic exam, and sural nerve conduction velocity (sNCV).
  • Presentation of Preliminary Data from Phase 2 Trial to Evaluate SB-509 for the Treatment of Amyotrophic Lateral Sclerosis (ALS): In December 2009, preliminary data were presented from the first subjects enrolled in Sangamo's Phase 2 clinical trial, SB-509-801. The data demonstrated an approximate doubling of the frequency of improved muscle function at day 120 post-treatment in subjects with ALS who received two treatments of SB-509 (32%) compared to matched historic controls (17%).
  • Initiation of Two Clinical Trials of a ZFP Nuclease (ZFN)-based Therapeutic for HIV and Presentation of Preliminary Data From a Treated Subject:  In February 2009, Sangamo and its collaborators at the University of Pennsylvania Medical School initiated the first Phase 1 safety trial of SB-728-T for the treatment of HIV/AIDS and in September 2009, the Company announced the initiation of a second Sangamo-sponsored Phase 1 trial. Preliminary data from the University of Pennsylvania investigator-sponsored study were presented in January 2010.  The data were from a single HIV- positive subject treated with SB-728-T who, as part of the study, began a defined structured treatment interruption (STI).  During the study, the subject's CD4+ T-cell count, number of circulating ZFN-modified cells and viral load were measured periodically.  In addition, rectal biopsies were taken prior to treatment and at the end of the STI period to monitor levels of CD4+ and ZFN-modified T-cells in the gut associated lymphoid tissue (GALT), a major reservoir of immune cells and a critical reservoir of HIV infection.  As expected, the subject's viral load increas
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
    2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
    3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
    4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
    5. Sangamo Announces Pricing of Public Offering of Common Stock
    6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
    7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
    8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
    9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
    10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
    11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
    (Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
    (Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
    (Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
    Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
    ... U.S. Department of Energys Brookhaven National Laboratory have developed ... and micrometer-sized particles. The method, based on designed DNA ... to manipulate the structure and therefore the properties ... be of interest to industry. For example, such fine-tuning ...
    ... 12 BioReliance Corporation, a,leading contract services ... contracted with Gentronix to offer their,GreenScreen HC ... of BioReliance,s portfolio of,genotoxicity screening services. GreenScreen ... pharmaceutical companies to test for genotoxic potential,earlier ...
    ... Inc. (Nasdaq:,PPDI) today announced Daniel G. Darazsdi has ... position on October 1. Mr. Darazsdi, 47, ... a $34 billion diversified technology and manufacturing,leader, where ... CFO of finance,transformation and operations. Over the years ...
    Cached Biology Technology:New DNA-based technique for assembly of nano- and micro-sized particles 2BioReliance Launches Next-Generation Genotoxicity Screening Service 2PPD Names Daniel Darazsdi as Chief Financial Officer 2PPD Names Daniel Darazsdi as Chief Financial Officer 3
    (Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
    (Date:7/9/2014)... may be on the verge of an economy driven by ... than coal and is undergoing a production boom. It has ... recent research is casting serious doubts over just how climate-friendly ... Engineering News (C&EN), the weekly news magazine of the ... senior correspondent at C&EN, explains that when burned as a ...
    (Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
    Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
    ... span of a common rat, the 10 to 30 year ... to East Africa, is impressive. And compared to the human ... to aging, maintaining high activity, bone health, reproductive capacity, and ... in Israel and the United States is working to uncover ...
    ... during pregnancy are uncommon, but the prevalence of heart disease ... more women delay pregnancy until they are older. These women, ... tend to have higher cholesterol levels and are at greater ... research has shown that the heart typically functions better during ...
    ... summer season is in full swing, many of us will be ... have some unwanted guests in the form of mosquitoes. Mosquitoes ... Syed, a mosquito biologist with the University of Notre Dame,s Eck ... determining how they do it. In short, it,s because of ...
    Cached Biology News:Naked mole rat may hold the secret to long life 2UCLA study looks at why heart attacks cause so much more damage in late pregnancy 2Mosquitoes -- how we smell is why they bite, research shows 2
    ... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
    ... Costar strip ejector is a unique product ... strips from their holder. Linkage: This CLS ... to easily match Cornings product number. If ... the old Sigma-Aldrich number (Z71,314-7) or contact ...
    ... hood ventilates and purifies hazardous chemical ... exhaust. Bonded charcoal filters remove most ... clearance (with access shield open) accommodates ... options include final HEPA filter, work ...
    Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
    Biology Products: